🇺🇸 JNJ 28431754 in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 10

Most-reported reactions

1. Asbestosis — 1 report (10%)
2. Atelectasis — 1 report (10%)
3. Atrial Fibrillation — 1 report (10%)
4. Biliary Tract Disorder — 1 report (10%)
5. Blood Creatinine Increased — 1 report (10%)
6. Cholangitis Sclerosing — 1 report (10%)
7. Dehydration — 1 report (10%)
8. Diabetic Ketoacidosis — 1 report (10%)
9. Dilatation Ventricular — 1 report (10%)
10. Drug-Induced Liver Injury — 1 report (10%)

Source database →

Frequently asked questions

Is JNJ 28431754 approved in United States?

JNJ 28431754 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for JNJ 28431754 in United States?

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is the originator. The local marketing authorisation holder may differ — check the official source linked above.